Sibeprenlimab, formerly known as VIS649, appears to be a innovative monoclonal agent demonstrating significant capability in the management of complement-mediated diseases . This unique approach inhibits C5a, a critical mediator participating in the destructive pathway, presenting a substantial advantage over current therapies. Initial clinical res